YELLOW FEVER

This early-stage study tested a new yellow fever vaccine (MVA-BN-YF) in 92 healthy adults aged 18-45. The goal was to check if the vaccine is safe and triggers a strong immune response, with some groups receiving an extra ingredient (adjuvant) to boost effectiveness. Results will…

This early-stage study tested two new vaccines, one for yellow fever and one for rabies, in 112 healthy adults aged 18 to 40. The main goal was to check safety and see how well the vaccines trigger an immune response. Researchers gave different doses to find the best balance of s…

This early-stage trial tested a new inactivated yellow fever vaccine called HydroVax-002 YFV in 26 healthy adults aged 18 to 49. Participants received two shots of either a low or high dose of the vaccine or a placebo, given one month apart. The main goal was to check safety and …

This study tested a new yellow fever vaccine (vYF) in 254 healthy adults aged 18 and older in Japan. Participants received one shot, and researchers checked for safety and immune response after about a month. The goal was to see if the vaccine triggers enough protection against y…

This study looked at how past infections and damage to lymph nodes might weaken the body's ability to build long-term protection from the yellow fever vaccine. Researchers studied 43 adults in Uganda and Minnesota, taking blood and lymph node samples before and after vaccination.…

This study looked at how healthy adults' immune systems respond to the yellow fever vaccine. 239 people aged 18-45 received the vaccine and were monitored for up to a year. The goal was to understand the body's T cell responses to a viral infection, using the safe vaccine as a mo…